ArticleOncoimmunology2015

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.

Neil L Berinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.